Ironwood Pharmaceuticals (IRWD) : During the past 4 weeks, traders have been relatively bearish on Ironwood Pharmaceuticals (IRWD), hence the stock is down -0.84% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.2% relative to the S&P 500. The 4-week change in the price of the stock is -0.97% and the stock has fallen -2.71% in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.39% and the 50-Day Moving Average is 1.39%.The 200 Day SMA reached 14.88%. Ironwood Pharmaceuticals, Inc. is up 0.08% in the last 3-month period. Year-to-Date the stock performance stands at 14.41%.
Ironwood Pharmaceuticals (NASDAQ:IRWD): The stock opened in the green at $13.44 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $13.48 and a low of $13.14 for the day. The stock did not find buyers even at the lows and closed at $13.26 recording a loss of -0.67%. 458,277 shares exchanged hands during the trading day. The stock had closed at $13.35 in the previous days trading.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.